Regulatory support for the development of a stem cell therapy and device for the treatment of Parkinson’s Disease
Boyds provided regulatory support to an academic institution client with an exciting proposal for a first-in-human stem cell therapy trial involving a medical device for the treatment of Parkinson’s Disease.
Boyds provided services to assist an EU Sponsor with the set up and ongoing site management of a study in patients with advanced metastatic breast cancer in the UK and Spain.
Boyds was engaged to support a client in the US with study start-up services in the UK and France for a gene therapy study in patients with an ocular condition.
The client was an early-stage start-up in the pre-clinical stage of developing a suite of gene therapy products for a cardiovascular indication.
The client came to Boyds with an exciting cell therapy programme that released its active molecule selectively in solid tumour cells.
Boyds played an important role in the formation of academia spin-out, Axovia, by providing technical and strategic support, alongside product development plans for the company’s drug programmes.